EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma

EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma

Purpose. This study investigates the efficacy and toxicity of daily oral etoposide in chemotherapy for non-heavily pretreated advanced and metastatic soft tissue sarcoma (STS).

Bibliographic Details
Main Authors:	H. Jan Keizer, Derek Crowther, Ole Steen Nielsen, Allan T. Van Oosterom, Javier Hornedo Muguiro, Christine Van Pottelberghe, Renier Somers, Thomas Tursz
Format:	Article
Language:	English
Published:	Hindawi Limited 1997-01-01
Series:	Sarcoma
Online Access:	http://dx.doi.org/10.1080/13577149778371

Similar Items

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas. The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
by: Ole S. Nielsen, et al.
Published: (2000-01-01)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
by: Axel Le Cesne, et al.
Published: (2019-08-01)

La actividad e instituciones asistenciales de las Iglesias: su garantía y promoción ante el derecho estatal y los acuerdos con éstas
by: Antonio Hornedo Muguiro
Published: (1991-04-01)

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients
by: G. Huygh, et al.
Published: (2006-01-01)

iCREATE: imaging features of primary and metastatic alveolar soft part sarcoma from the EORTC CREATE study
by: Naami Charlotte Mcaddy, et al.
Published: (2020-10-01)

Cisplatin & IV Etoposide combination in the treatment of advanced breast cancer pretreated with anthracyclines
by: Anmar Allami
Published: (2019-06-01)

Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis
by: Shiro Saito, et al.
Published: (2020-09-01)

A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma
by: Charles R. Crawley, et al.
Published: (1997-01-01)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
by: Khoshnevisan Alireza, et al.
Published: (2012-05-01)

Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants
by: Chunsheng Wu, et al.
Published: (2020-01-01)

Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma
by: Veit Bücklein, et al.
Published: (2020-01-01)

Measuring Prostate Cancer Quality of Life:Psychometric Properties of the EORTC-C30 and EORTC-PR25
by: Yu-Jun Chang, et al.
Published: (2008)

International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26
by: Monika Sztankay, et al.
Published: (2018-11-01)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
by: Wonkyo Shin, et al.
Published: (2018-05-01)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
by: Annelies Requilé, et al.
Published: (2017-01-01)

A Sarcoma at the Site of Previous Extravasation of Adriamycin
by: Joris Ceulemans, et al.
Published: (2002-01-01)

Validity, reliability and understanding of the EORTC-C30 and EORTC-BR23, quality of life questionnaires specific for breast cancer
by: Fernanda Alessandra Silva Michels, et al.
Published: (2013-06-01)

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)
by: A. Poveda, et al.
Published: (2005-01-01)

Probable Etoposide Interaction with Echinacea
by: Bossaer, John B., et al.
Published: (2012)

Etoposide Therapy for Recurrent Gliomas
by: J Gordon Millichap
Published: (1997-06-01)

Development of Pro-Drugs For Etoposide
by: Muahtaq, Shaid
Published: (2010)

Cross-cultural analyses of the EORTC QLQ-C30
by: Scott, Neil W.
Published: (2007)

Psychometric properties of the EORTC QLQ-C30 in Uganda
by: Allen Naamala, et al.
Published: (2021-04-01)

The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30
by: Helen McTaggart-Cowan, et al.
Published: (2019-04-01)

Quality of life in patients with lung cancer in Taiwan: Validation of a Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-LC13
by: Tseng, Chun-Hua, et al.
Published: (2005)

Measurement Feasibility and Equivalence of Paper and Touch-screen Versions of the EORTC QLQ-C30 and the EORTC QLQ-PR25 Questionnaires in Prostate Cancer Patients
by: Chiao-Ling Peng, et al.
Published: (2010)

The process of forward-backward translation of the EORTC QLQ-SWB into Persian
by: Sepideh Omidvari, et al.
Published: (2014-12-01)

Validation of EORTC IN-PATSAT32 for Chinese patients with gastrointestinal cancer
by: Zhang J, et al.
Published: (2014-09-01)

The communication between cancer patients and professionals. The EORTC communication questionnaire
by: Juan Ignacio Arraras, et al.
Published: (2017-05-01)

Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires
by: Ficko Sanja Ledinski, et al.
Published: (2019-09-01)

Clinical and laboratory studies of etoposide phosphate, a novel pro-drug of etoposide : with special reference to pharmcokinetically guided dosing
by: Porter, David James
Published: (1998)

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables
by: J Fernandez-Gomez, et al.
Published: (2011-10-01)

Associations between the spiritual well-being (EORTC QLQ-SWB32) and quality of life (EORTC QLQ-C30) of patients receiving palliative care for cancer in Cyprus
by: Maria Kyranou, et al.
Published: (2021-08-01)

Refractory Choriocarcinoma: Complete Response With Oral Etoposide
by: Manikandan Dhanushkodi, et al.
Published: (2017-10-01)

Bilateral macular ischemia following oral etoposide
by: Abhishek Das, et al.
Published: (2020-01-01)

Etoposide induces nuclear re-localisation of AID.
by: Laurens J Lambert, et al.
Published: (2013-01-01)

Hypersensitivity reaction to etoposide. A case report
by: M. Mullera Martí, et al.
Published: (2014-05-01)

Hypersensitivity to Etoposide in Case of Metastatic Gestational Choriocarcinoma
by: Biljana Lazović, et al.
Published: (2013-09-01)

Numerical analysis of etoposide induced DNA breaks.
by: Aida Muslimović, et al.
Published: (2009-06-01)

Cell-cell contact induced resistance to etoposide
by: Oloumi, Arusha
Published: (2009)